A groundbreaking immunotherapy trial has achieved zero cancer recurrence in 32 patients over nearly three years, challenging the conventional treatment approach that has dominated colorectal cancer care for decades.
At a Glance
- All 32 trial participants remained cancer-free after 33 months, compared to a 25% relapse rate under standard treatment protocols
- The NEOPRISM-CRC trial used nine weeks of preoperative pembrolizumab immunotherapy instead of postoperative chemotherapy, reducing patient toxicity
- Fifty-nine percent of patients achieved complete tumor disappearance before surgery, with researchers describing cancers as having “melted away”
- Results target a specific genetic subtype—mismatch repair-deficient cancers—representing 12-15% of colorectal cases, though broader applications may follow
- The trial’s success could reshape treatment guidelines and reduce reliance on traditional chemotherapy for high-risk patients
A Paradigm Shift in Cancer Treatment Timing
For decades, the standard colorectal cancer playbook has remained largely unchanged: surgery first, chemotherapy second. The NEOPRISM-CRC trial, led by researchers at UCL and UCLH, upends this conventional wisdom. Thirty-two patients with stage two or three bowel cancer received nine weeks of pembrolizumab immunotherapy before surgery, avoiding the traditional post-operative chemotherapy entirely. After 33 months of follow-up, not a single patient experienced cancer recurrence—a stark contrast to the approximately 25% relapse rate patients typically face under standard care protocols.
Dramatic Tumor Response Rates Challenge Traditional Methods
The trial’s biological results proved equally striking. Fifty-nine percent of patients achieved pathological complete response, meaning surgeons found no detectable cancer tissue at the time of operation. In some cases, physicians described the cancers as having “melted away.” This aggressive tumor shrinkage before surgery enabled sphincter-preserving procedures for rectal cancer patients, preserving organ function and quality of life—outcomes that matter profoundly to patients facing cancer treatment. The rapid pre-surgical response also provided real-time evidence of treatment efficacy through circulating tumor DNA monitoring, allowing physicians to track success at the molecular level.
Targeting a Genetic Vulnerability in Cancer Cells
The trial focused specifically on patients with mismatch repair-deficient or microsatellite instability-high tumors—genetic subtypes representing 12-15% of colorectal cancers. These tumors carry thousands of mutations, making them highly visible to the immune system. Pembrolizumab, a checkpoint inhibitor, essentially removes the brakes cancer cells place on immune surveillance, allowing the body’s natural defenses to recognize and attack malignant cells. This genetic specificity matters: while the results are remarkable within this subgroup, they underscore that cancer treatment is increasingly moving toward precision medicine rather than one-size-fits-all approaches.
Reducing Chemotherapy Burden and Improving Patient Experience
Beyond survival statistics lies a fundamental quality-of-life consideration. Chemotherapy carries well-documented toxicities—peripheral neuropathy, gastrointestinal complications, and prolonged fatigue—that can persist for months or years after treatment concludes. By shifting to preoperative immunotherapy, patients potentially avoid these debilitating side effects while achieving superior long-term outcomes. For working-age adults and those balancing cancer treatment with family responsibilities, this represents a meaningful reduction in treatment burden. The trial’s zero-recurrence rate suggests this approach doesn’t sacrifice efficacy for tolerability.
Colon cancer breakthrough keeps patients cancer-free for nearly 3 years https://t.co/zUb4YkASJ1
— Un1v3rs0 Z3r0 (@Un1v3rs0Z3r0) May 6, 2026
Implications for Healthcare Systems and Drug Approval Pathways
The findings arrive as regulatory agencies worldwide accelerate approvals for immunotherapy-based cancer treatments. In 2024, the FDA granted dostarlimab—another immunotherapy used in similar trials—”Breakthrough Therapy Designation,” expediting its review. The NEOPRISM-CRC results strengthen the case for redefining colorectal cancer treatment guidelines, potentially shifting pembrolizumab from a late-stage option to a first-line intervention for high-risk patients. However, challenges remain: the trial enrolled only 32 patients across five UK hospitals, and larger phase-three randomized trials are underway to confirm generalizability. Additionally, access to genetic testing for mismatch repair deficiency remains limited in many healthcare systems, creating potential equity gaps in treatment availability.
Sources:
Breakthrough Bowel Cancer Trial Leaves Patients Cancer-Free for Nearly 3 Years
Patients remain cancer-free nearly 3 years after receiving experimental immunotherapy
Rectal cancer disappears after experimental use of immunotherapy
